Arkolith/Insider Trading/KNSA/Form 4

Ragosa Mark

CHIEF FINANCIAL OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Dec 10, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 8, 2025Option exercise(M)11K$10.76$113K74K
Dec 8, 2025Option exercise(M)16K$11.97$193K63K
Dec 8, 2025Option exercise(M)16K$11.10$179K47K
Dec 8, 2025Sell(S)43K$41.49$1.8M31K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 8, 2025Option exercise(M)16K—$012K
Dec 8, 2025Option exercise(M)11K—$014K
Dec 8, 2025Option exercise(M)16K—$05K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001835458-25-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML